Charles River Laboratories (NYSE:CRL) is facing headwind issues in its research and model services, or RMS segment, which contributes approximately 61% of the total net sales of the company and posted $182.5 million revenue in the first quarter of 2013. The total revenue declined by 2.1% compared to the previous year, but it grew by about 6% compared to its previous quarter. Most of its biopharmaceutical clients set their budgets and spending priorities for the coming year in the last quarter of the year. And hence, the last quarters never generate higher revenue. As a result, the quarterly growth, even though it is impressive, doesn't look promising to me.
Charles River acquired Accugenix and Vital River under its...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|